Category survey

Characterization of the Fidelity to PD of a Unique Rat Model Investments < €500k United States of America 2016    

The role of G3BP1 in mutant SOD1-mediated familial ALS Investments < €500k United States of America 2016    

Seeded transmission of SOD1 misfolding Investments < €500k United States of America 2016    

Somatic inactivation of the SNCA locus: a new approach to the understanding and treatment of Parkinsons Disease Investments < €500k United States of America 2016    

Imaging agents for synucleinopathy drug discovery Investments < €500k United States of America 2016    

Understanding PDI-related neurotoxicity and advancing preventative approaches Investments < €500k United States of America 2016    

Striatal Nurr1 activity facilitates the dyskinetic state: A novel therapeutic target Investments < €500k United States of America 2016    

SMN dysfunction in FUS-dependent ALS Investments < €500k United States of America 2016    

Gene Therapy Targeting Striatal cGMP signaling in experimental parkinsonism Investments < €500k United States of America 2016    

Endogenous petides as markers of abnormal SOD-1 protein in familial and sporadic ALS Investments < €500k United States of America 2016    

Global RNA Interference Therapy for Huntingtons Disease Investments < €500k United States of America 2016    

Novel 3D brain tissue-based screening assay for targeting microglia in CNS neurodegeneration Investments < €500k United States of America 2016    

Translational regulation by DJ-1 Investments < €500k United States of America 2016    

PINK1 regulation of neuronal and mitochondrial homeostasis Investments < €500k United States of America 2016    

Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA Investments < €500k United States of America 2016    

Activation of the GPCR Smoothened as a treatment of L-Dopa Induced dyskinesia Investments < €500k United States of America 2016    

Neural and Kinematic Features of Freezing of Gait for Adaptive Neurostimulation Investments < €500k United States of America 2016    

Apoptotic neuronal cells serve as sources for spreading of human a-synuclein pathology in the brain Investments < €500k United States of America 2016    

Addressing the contribution of JNK3 to axonal pathology in Huntingtons disease Investments < €500k United States of America 2016    

Mechanisms of LRRK2 Mediated Dopaminergic Axonal Degeneration and Synaptic Transmission Deficits Investments < €500k United States of America 2016    

TTR and C9ORF72 in ALS and related disorders Investments < €500k United States of America 2016    

Elucidating the mechanism of mitochondrial quality control in Drosophila Investments < €500k United States of America 2016    

Linking Olfactory deficits to Neurodegenerative Disorders Investments < €500k United States of America 2016    

Investigating mechanisms of UBQLN2-mediated neurodegenerative disease Investments < €500k United States of America 2016    

A novel dual hit model of environmental risk factors for Parkinsons Disease Investments < €500k United States of America 2016    

G-quadruplex Structures as Targets and Tools in ALS Investments < €500k United States of America 2016    

Striatal systems and mechanisms regulating L-dopa-induced dyskinesias in Parkinsons disease Investments < €500k United States of America 2016    

Loss of a cohort of axonal mRNAs as a result of reduced SMN levels. Investments < €500k United States of America 2016    

Tongue- and Jaw-Specific Contributions to Vowel Acoustic Changes: Towards a Mechanistic Model of Intelligibility Loss and Recovery in Dysarthria Investments < €500k United States of America 2016    

SYNJ1 Mediates a Novel Signaling Pathway in Parkinsons Disease Investments < €500k United States of America 2016    

Does TDP-43 dysfunction in astrocytes trigger motor neuron degeneration? Investments < €500k United States of America 2016    

Investigating the response of FUS/TLS to excitotoxic insult Investments < €500k United States of America 2016    

A new antibody/RNAi combination therapy strategy for ALS Investments < €500k United States of America 2016    

Modulating the Nucleopathy caused by FUS Mutants of ALS Investments < €500k United States of America 2016    

A new approach to modeling ALS based on TBK1 mutation in mice Investments < €500k United States of America 2016    

Genetic Susceptibility to Manganese Neurotoxicity Investments < €500k United States of America 2016    

Roles of heat shock protein 110 in modulating amyloid neurotoxicity Investments < €500k United States of America 2016    

Design and development of a mixed reality system for skilled locomotor training in individuals with Parkinsons disease Investments < €500k United States of America 2016    

Neuroprotection by MC1R as the basis for the melanoma-Parkinsons disease link Investments < €500k United States of America 2016    

Mitochondrial SIRT3 in Huntingtons disease Investments < €500k United States of America 2016    

Genome editing in HD iPS cells to reduce mutant and total Huntington expression Investments < €500k United States of America 2016    

Gene Therapy for Upper Airway and Respiratory Insufficiency in an ALS Mouse Model Investments < €500k United States of America 2016    

Cellular mechanisms underlying detoxification of mutant Huntingtin Investments < €500k United States of America 2016    

Investigating the contributions of astrocyte gap junctions to ALS disease progression Investments < €500k United States of America 2016    

NG2 cells in Huntingtons disease Investments < €500k United States of America 2016    

A synthetic vesicle to carry modifier compounds to axonal blocks induced by pathogenic polyQ Investments < €500k United States of America 2016    

Development of Analog Sensitive PINK1 Animal Model and iPS Cells Investments < €500k United States of America 2016    

Plasticity of bridge collaterals in Parkinonian state and treatment Investments < €500k United States of America 2016    

Lake Cyanobacterial Harmful Algal Bloom Mapping and Analysis Platform (CHAB-MAP) Investments < €500k United States of America 2016    

A Prospective Study of Nicotine from Edible Solanaceae and Risk of Parkinson Disease Investments < €500k United States of America 2016